Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 6318 | 26.55 |
09:34 ET | 400 | 26.3 |
09:36 ET | 359 | 26.28 |
09:38 ET | 100 | 26.27 |
09:41 ET | 2350 | 26.36 |
09:43 ET | 1500 | 26.31 |
09:45 ET | 100 | 26.31 |
09:48 ET | 100 | 26.315 |
09:50 ET | 100 | 26.325 |
09:52 ET | 100 | 26.32 |
09:54 ET | 500 | 26.16 |
09:56 ET | 350 | 26.12 |
09:59 ET | 200 | 26.12 |
10:01 ET | 600 | 25.96 |
10:03 ET | 1540 | 25.86 |
10:06 ET | 777 | 25.86 |
10:08 ET | 3540 | 25.9401 |
10:10 ET | 1500 | 25.915 |
10:12 ET | 1301 | 25.91 |
10:14 ET | 1608 | 25.85 |
10:15 ET | 3014 | 25.91 |
10:17 ET | 1039 | 25.86 |
10:19 ET | 1550 | 25.945 |
10:21 ET | 100 | 25.95 |
10:24 ET | 594 | 25.96 |
10:26 ET | 320 | 26.02 |
10:28 ET | 341 | 26.01 |
10:30 ET | 1700 | 25.93 |
10:32 ET | 5589 | 25.945 |
10:33 ET | 12389 | 26.08 |
10:35 ET | 1944 | 26.03 |
10:37 ET | 1477 | 26.06 |
10:39 ET | 800 | 26.055 |
10:42 ET | 700 | 25.91 |
10:44 ET | 862 | 25.94 |
10:46 ET | 1100 | 25.915 |
10:48 ET | 1563 | 26.04 |
10:50 ET | 2716 | 26.04 |
10:51 ET | 1430 | 26.15 |
10:53 ET | 1055 | 26.11 |
10:55 ET | 600 | 26.08 |
10:57 ET | 100 | 26.08 |
11:00 ET | 700 | 26.02 |
11:02 ET | 3153 | 26.07 |
11:04 ET | 500 | 26.08 |
11:08 ET | 4826 | 26.01 |
11:09 ET | 1774 | 25.985 |
11:11 ET | 800 | 25.96 |
11:13 ET | 600 | 25.98 |
11:15 ET | 3397 | 25.885 |
11:18 ET | 3915 | 25.93 |
11:20 ET | 600 | 25.95 |
11:22 ET | 400 | 25.92 |
11:24 ET | 100 | 25.92 |
11:26 ET | 767 | 25.89 |
11:27 ET | 1348 | 25.935 |
11:29 ET | 425 | 25.92 |
11:31 ET | 1319 | 25.97 |
11:33 ET | 500 | 25.95 |
11:38 ET | 200 | 25.92 |
11:40 ET | 851 | 25.9 |
11:42 ET | 1000 | 25.88 |
11:44 ET | 200 | 25.88 |
11:45 ET | 1189 | 25.84 |
11:47 ET | 1818 | 25.88 |
11:49 ET | 605 | 25.85 |
11:51 ET | 479 | 25.82 |
11:54 ET | 300 | 25.85 |
11:56 ET | 300 | 25.82 |
11:58 ET | 309 | 25.87 |
12:00 ET | 300 | 25.82 |
12:02 ET | 14261 | 25.82 |
12:03 ET | 100 | 25.82 |
12:05 ET | 100 | 25.81 |
12:07 ET | 700 | 25.81 |
12:09 ET | 500 | 25.79 |
12:12 ET | 1239 | 25.77 |
12:14 ET | 1375 | 25.82 |
12:16 ET | 300 | 25.79 |
12:18 ET | 400 | 25.78 |
12:20 ET | 2825 | 25.795 |
12:21 ET | 510 | 25.81 |
12:23 ET | 500 | 25.77 |
12:25 ET | 100 | 25.79 |
12:27 ET | 900 | 25.705 |
12:30 ET | 744 | 25.68 |
12:32 ET | 400 | 25.63 |
12:34 ET | 700 | 25.655 |
12:36 ET | 100 | 25.64 |
12:38 ET | 200 | 25.635 |
12:39 ET | 2478 | 25.69 |
12:41 ET | 2097 | 25.698 |
12:43 ET | 700 | 25.73 |
12:45 ET | 3649 | 25.77 |
12:48 ET | 2076 | 25.78 |
12:50 ET | 100 | 25.775 |
12:52 ET | 100 | 25.78 |
12:54 ET | 4160 | 25.83 |
12:56 ET | 203 | 25.825 |
12:57 ET | 400 | 25.83 |
12:59 ET | 1527 | 25.86 |
01:01 ET | 4008 | 25.895 |
01:03 ET | 700 | 25.87 |
01:06 ET | 100 | 25.87 |
01:08 ET | 618 | 25.9 |
01:10 ET | 1000 | 25.94 |
01:12 ET | 2528 | 25.99 |
01:14 ET | 1576 | 25.9999 |
01:15 ET | 4186 | 25.96 |
01:17 ET | 639 | 25.955 |
01:19 ET | 6571 | 25.895 |
01:21 ET | 500 | 25.895 |
01:24 ET | 4812 | 25.87 |
01:26 ET | 7981 | 25.955 |
01:28 ET | 1400 | 25.94 |
01:30 ET | 554 | 25.935 |
01:32 ET | 1887 | 25.93 |
01:33 ET | 800 | 25.915 |
01:35 ET | 661 | 25.925 |
01:37 ET | 2036 | 25.945 |
01:39 ET | 1600 | 25.96 |
01:42 ET | 5001 | 25.92 |
01:44 ET | 1164 | 25.915 |
01:46 ET | 718 | 25.92 |
01:48 ET | 2417 | 25.935 |
01:50 ET | 939 | 25.935 |
01:51 ET | 1386 | 25.935 |
01:53 ET | 3558 | 25.91 |
01:55 ET | 3093 | 25.9 |
01:57 ET | 1763 | 25.87 |
02:00 ET | 2083 | 25.875 |
02:02 ET | 1749 | 25.85 |
02:04 ET | 1100 | 25.865 |
02:06 ET | 821 | 25.895 |
02:08 ET | 1342 | 25.915 |
02:09 ET | 3079 | 25.93 |
02:11 ET | 379 | 25.915 |
02:13 ET | 750 | 25.92 |
02:15 ET | 1314 | 25.92 |
02:18 ET | 3954 | 25.89 |
02:20 ET | 1885 | 25.89 |
02:22 ET | 721 | 25.89 |
02:24 ET | 668 | 25.89 |
02:26 ET | 1590 | 25.895 |
02:27 ET | 5025 | 25.915 |
02:29 ET | 3462 | 25.98 |
02:31 ET | 3616 | 25.91 |
02:33 ET | 20380 | 25.73 |
02:36 ET | 15419 | 25.75 |
02:38 ET | 1213 | 25.75 |
02:40 ET | 817 | 25.74 |
02:42 ET | 4067 | 25.775 |
02:44 ET | 906 | 25.79 |
02:45 ET | 1300 | 25.78 |
02:47 ET | 3200 | 25.765 |
02:49 ET | 500 | 25.76 |
02:51 ET | 1346 | 25.785 |
02:54 ET | 953 | 25.785 |
02:56 ET | 1934 | 25.81 |
02:58 ET | 1489 | 25.8 |
03:00 ET | 1875 | 25.825 |
03:02 ET | 704 | 25.825 |
03:03 ET | 2843 | 25.87 |
03:05 ET | 4349 | 25.855 |
03:07 ET | 1100 | 25.86 |
03:09 ET | 1243 | 25.85 |
03:12 ET | 5054 | 25.94 |
03:14 ET | 3002 | 25.97 |
03:16 ET | 6173 | 26 |
03:18 ET | 3763 | 25.78 |
03:20 ET | 26993 | 26 |
03:21 ET | 1915 | 25.87 |
03:23 ET | 1325 | 25.76 |
03:25 ET | 17605 | 25.98 |
03:27 ET | 900 | 25.935 |
03:30 ET | 2893 | 25.94 |
03:32 ET | 3344 | 25.93 |
03:34 ET | 500 | 25.91 |
03:36 ET | 6154 | 26.055 |
03:38 ET | 6869 | 26.147 |
03:39 ET | 2907 | 26.13 |
03:41 ET | 5099 | 26.165 |
03:43 ET | 1520 | 26.135 |
03:45 ET | 9463 | 26.185 |
03:48 ET | 2650 | 26.09 |
03:50 ET | 2366 | 25.96 |
03:52 ET | 4598 | 25.86 |
03:54 ET | 36826 | 26 |
03:56 ET | 23763 | 26 |
03:57 ET | 38518 | 25.98 |
03:59 ET | 58687 | 26 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 3.8B | -13.8x | --- |
Avidity Biosciences Inc | 3.8B | -13.4x | --- |
Crinetics Pharmaceuticals Inc | 3.6B | -12.0x | --- |
Merus NV | 3.8B | -20.8x | --- |
Immunitybio Inc | 4.1B | -5.6x | --- |
Dyne Therapeutics Inc | 3.3B | -8.3x | --- |
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.8B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-1.89 |
Book Value | $4.24 |
P/E Ratio | -13.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.